STAT3 and B-cell chronic lymphocytic leukemia: Similarly, ibrutinib has been shown to modulate the immunosuppressive CLL microenvironment, through the STAT3-mediated suppression of regulatory B cell function and inhibition of the PD-1/PD-L1 pathway56.